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Background and Aims: Disability-adjusted life years (DALYs) are an important
measure of the global burden of disease that informs patient outcomes and policy
decision-making. Our study aimed to compare the DALYs saved by endovascular
thrombectomy (EVT) in the Australasian-based EXTEND-IA trial vs. clinical registry data
from EVT in Australian routine clinical practice.
Methods: The 3-month modified Rankin scale (mRS) outcome and treatment status of
consecutively enrolled Australian patients with large vessel occlusion (LVO) stroke were
taken from the International Stroke Perfusion Imaging Registry (INSPIRE). DALYs were
calculated as the summation of years of life lost (YLL) due to premature death and years
lived with a disability (YLD). A generalized linear model (GLM) with gamma family and
log link was used to compare the difference in DALYs for patients receiving/not receiving
EVT while controlling for key covariates. Ordered logit regression model was utilized to
compare the difference in functional outcome at 3months between the treatment groups.
Cox regression analysis was undertaken to compare the difference in survival over
an 18-year time horizon. Estimated long-term DALYs saved based on the EXTEND-IA
randomized controlled trial (RCT) results were used as the comparator.
Results: INSPIRE patients who received EVT treatment only achieved nominally better
functional outcomes than the non-EVT group (p = 0.181) at 3 months. There was no
significant survival gain from EVT over the first 3 months of stroke in both INSPIRE
and EXTEND-IA patients. However, measured against no EVT in the long-term, EVT
in INSPIRE was associated with no significant survival gain [hazard ratio (HR): 0.92,
95% confidence interval (CI): 0.78–1.08, p = 0.287] compared with the survival benefit
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extrapolated from the EXTEND-IA trial (HR: 0.42, 95% CI: 0.22–0.82, p = 0.01]. Offering
EVT to patients with LVO stroke was also associated with fewer DALYs lost (11.04, 95%
CI: 10.45–11.62) than those not receiving EVT in INSPIRE (12.13, 95% CI: 11.75–12.51),
a reduction of −1.09 DALY (95% CI: −1.76 to −0.43, p = 0.002). The absolute
magnitude of the treatment effect was lower than that seen in EXTEND-IA (−2.72 DALY
reduction in EVT vs non-EVT patients).
Conclusions: EVT for the treatment of LVO in a registry of routine care was associated
with significantly lower DALYs lost than medical care alone, but the saved DALYs are
less than those reported in clinical trials, as there were major differences in the baseline
characteristics of the patients.
Keywords: thrombectomy, disability adjusted life year (DALY), INSPIRE registry, real-world data analysis,
randomized controlled clinical trial (RCT)
INTRODUCTION
Endovascular thrombectomy (EVT) is associated with
significantly improved disability-free survival compared
with the previous standard of care, intravenous thrombolysis
(IVT) (1–6). One of these positive normal time window EVT
trials, EXTEND-IA, in which selection by perfusion imaging
demonstration of “target mismatch” was mandatory, reported
that EVT led to a doubling of the number of people living
disability free (generalized odds ratio (OR) 2.0, 95% confidence
interval (CI): 1.2–3.8, p = 0.006 on ordinal analysis of modified
Rankin scale (mRS) score) (6). However, analysis based on
routine clinical practice following implementation of trial
evidence is not always the same as that observed in randomized
controlled trials (RCTs). Patients may be treated outside of the
strict trial criteria. For example, most trials of EVT had an age
limit for inclusion. In a real-world study, elderly patients who
received EVT experienced higher rates of hemorrhage (40.7
vs. 9.3%, p < 0.001) without significantly improved functional
outcomes than a matched medical management cohort (7). A
previous study that examined the Disability-adjusted life years
(DALYs) lost based on the EXTEND-IA RCT, which utilized
perfusion imaging selection to identify patients with large vessel
occlusion (LVO) stroke for EVT, reported that EVT led to
significantly fewer lifetime DALYs lost than non-EVT (−2.72
DALY, p = 0.02) (8). However, DALY estimation from this study
may not be generalizable to real-world practice as perfusion
imaging selection (or the criteria if performed) for EVT is not
rigidly adhered to (or not performed at all in some countries).
DALYs were developed tomeasure the relative and total global
burden of all diseases using a common metric, which integrates
both mortality (years of life lost (YLL) due to premature death)
and morbidity (years of healthy life lost due to living with
a disability) (9). As an important metric of disease burden,
the DALYs can be used as the basis for resource allocation
and priority setting for stroke prevention, evidence-based
healthcare planning for acute stroke management, and post-
stroke rehabilitation services (10). They have been referenced
extensively in global health debates and decision-making (11).
DALYs can reveal the likely impact of stroke on a patient over
their remaining lifetime rather than at a single time point. Stroke,
as the leading cause of adult disability in Australia andworldwide,
leads to significantly more DALYs lost (116.4 million) annually
than coronary heart disease (82 million) (12, 13).
Even though there is controversy around the use of DALYs
as an outcome measure (14), they remain an important index
to quantify the disease burden (15). Given the important role
that DALYs play in informing policy decision-making, this study
aims to improve the evidence based on comparing the DALYs
saved from EVT in LVO stroke patients with LVO to assess the
impact of the implementation of EVT into routine clinical care
compared with the benefits reported in EXTEND-IA in Australia.
Other important clinical outcomes including 3-monthmRS score
and overall survival were also analyzed and compared.
METHODS
Study Population
We accessed the International Stroke Perfusion Imaging Registry
(INSPIRE), a registry of patients with stroke, to source the
baseline and 90-day clinical and imaging data for all Australian
patients with LVO defined as occlusions of the internal carotid
artery (ICA) and proximal segment (M1, M2) of the middle
cerebral artery over a 5-year period (2015–2019), regardless of
the baseline characteristics (e.g., volume of infarct core, etc.)
(16, 17). Routine multimodal computed tomography (CT: non-
contrast CT, perfusion CT, and CT angiography) was performed
on patients presenting with acute neurological deficits. Eligible
patients received thrombolysis prior to EVT. In routine clinical
practice, EVT is offered to patients with (i) the presence of
a LVO that is potentially retrievable, (ii) reasonable pre-stroke
function (mRS 0–3), and (iii) limited medical comorbidities.
In particular, if the patient was within 6 h of onset, perfusion
imaging criteria, such as used in EXTEND-IA, was not used to
exclude patients from therapy. Unless contraindicated, magnetic
resonance imaging (MRI) at 24 h post-stroke was standard
practice, in which case repeat imaging was carried out with
multimodal CT. The National Institute of Health Stroke Severity
(NIHSS), the primary index for stroke severity, was assessed
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immediately before treatment and 24 h imaging. In INSPIRE,
24-h Thrombolysis in Cerebral Infarction (TICI) Score is adopted
as reperfusion grades with 2b−3 being successful reperfusion
(18). All patients were assessed at 90 days post-stroke onset for
functional outcome using the mRS.
Written informed consent for participation in the study was
provided by all the patients. The Hunter New England Area
Health Service Human Research Ethics Committee reviewed and
approved the study protocol in 2012.
Estimation of DALY
A DALY is calculated as the summation of two components:
YLL due to premature death and years lived with a disability
(YLD). Lower DALYs indicate more disability-free life years after
the index stroke (one DALY indicates 1 year of disability-free
life lost).
YLL due to premature death are calculated as the difference
in life expectancy of an age-, sex-matched person from the
general Australian population and a stroke patient in a certain
mRS category. Patients post-stroke have a higher hazard ratio
(HR) of dying from all-cause mortality determined by their
mRS score at 3 months. All-cause mortality of the general
Australian population for each age and gender was adjusted
by the corresponding HR to estimate the life expectancy for
patients with stroke (19). The life table for the general Australian
population and the formula to recalculate the life expectancy
for stroke patients were sourced from the Australian Bureau of
Statistics (ABS) (20).
YLD are calculated by multiplying the life expectancy of a
stroke patient by a disability weight. The disability weights based
on mRS score were sourced from the study by Hong and Saver
(21). In the base case, DALYs were not adjusted by age weight
nor discounted, in accordance with the recommendation of the
World Health Organization (19). However, in the sensitivity
analysis, DALYs were discounted at an annual rate of 3%,
and age weighting was applied to examine the robustness
of base case results (19). Using individual patient-level data
from INSPIRE, DALYs (and the two components—YLL and
YLD) were calculated for each patient based on their 3-
month mRS score. The detailed calculations are provided in the
Supplementary Document.
Statistical Analysis
Descriptive analysis was undertaken of the baseline
characteristics of Australian patients receiving EVT vs. no
EVT using INSPIRE data and compared with their respective
groups in the Australasian-based EXTEND-IA trial. EXTEND-
IA was selected as the comparator since it offers the optimal
comparability of EVT/no EVT patients with INSPIRE, by
reporting the long-term DALY outcome using patient-level data
and comparing patients treated in the same centers and similar
medical systems by the same healthcare providers across the
country. Differences in baseline characteristics within INSPIRE
and between INSPIRE and EXTEND-IA were tested using T-test
or Wilcoxon rank-sum test depending on the distribution of
the variable (22). Within INSPIRE, (i) ordered logit regression
model was utilized to compare the difference in functional
outcome at 3 months between the treatment groups (23); (ii) Cox
regression model (survival analysis) was undertaken to explore
the difference in the projected survival over 18 years (from
3-month post-stroke onset) between the two treatment groups
(8). These analyses were also performed in a subgroup of patients
with intracranial ICA or M1 occlusions as this is the group with
the strongest evidence of benefit from thrombectomy. Eighteen
years were considered sufficient to capture the difference in
survival in the current study given the older age of many stroke
patients. The time-to-death for each individual was extracted
from the reconstructed life table for patients with stroke but was
censored at 18 years post the index stroke. Where a patient died
due to stroke (mRS = 6) prior to month 3, they were assigned
the maximal survival of 3 months. In the Cox regression model,
onset age, gender, baseline NIHSS, baseline infarct core volume,
and baseline penumbra volume were adjusted, which are in line
with the analysis from EXTEND-IA. Survival gain and DALYs
saved due to EVT within INSPIRE were compared with similar
outcomes (i.e., survival and DALYs saved from both EVT and no
EVT treatment groups) estimated from EXTEND-IA (6).
To estimate the difference in DALYs, YLL and YLD between
the two treatment groups, a generalized linear model (GLM)
with gamma distribution and log link was adopted given the
non-normal distribution of the DALY and its two components.
The selection of gamma distribution and link function was
informed by a modified Park test and link test (24). DALY was
the dependent variable, whereas the treatment status, onset age,
gender (male/female), time from stroke onset to hospital arrival
(min), baseline NIHSS, baseline penumbra volume, and IVT
treatment (Y/N) were entered as covariates. DALYs saved (i.e.,
between-group difference in DALYs) due to EVT from INSPIRE
and EXTEND-IA were directly compared. To further test the
difference in DALYs lost within INSPIRE by age, onset age was
also coded as a dummy variable and was included in the GLM
analysis. Bootstrapping with 2,000 iterations was undertaken to
further examine the robustness of results from GLM analysis.
All the analyses were performed using the STATA V16 statistical
package (StataCorp 2019, Stata Statistical Software: Release 16;
StataCorp LLC, College Station, TX, USA) and Microsoft Excel.
RESULTS
Study Populations
In total, from INSPIRE, 178 LVOpatients (mean age of 69.7 years,
53% male) received EVT vs. 584 LVO patients (mean age of 71.9
years, 52% male) who had medical treatment alone during the
study period (2015–19). The age distribution of patients from the
two treatment groups is shown in Supplementary Figure 1. The
median baseline NIHSS was 16 and 15 in the two groups with
similar interquartile ranges (IQRs). The baseline core volume
was not significantly different between the two groups, whereas
patients who received EVT had significantly higher penumbra
volume at baseline (88ml in the EVT group vs. 68ml in the
non-EVT group, p < 0.001). Approximately 48.3% of patients
in the EVT group had thrombolysis prior to EVT compared
with 59.3% in the non-EVT group, and 83% of patients received
EVT within 6 h of stroke onset. Patients who received EVT
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treatment only achieved nominally better functional outcomes
than the non-EVT group (p = 0.181) at 3 months and when
controlled for both time from stroke onset to hospital arrival
and successful reperfusion at 24 h (i.e., TICI 2b/3), and the
results were consistent (p = 0.382). Baseline characteristics and
3-month mRS outcomes of the study population are summarized
in Table 1 and Supplementary Figure 2. Three-month mRS
outcomes for subgroups with ICA or M1 occlusions, provided
in Supplementary Table 1, show that EVT was associated
with significantly better functional outcomes than patients not
receiving EVT (p= 0.017).
In comparison, the EXTEND-IA RCT recruited patients with
a mean age of 69 years (SD = 12), median NIHSS score of
15 (IQR: 12–19), and 49% males (6). The median baseline
core and perfusion lesion volumes were 12 vs. 18ml and
106 vs. 115ml in the EVT and no EVT treatment groups,
respectively. Generally, patients receiving EVT in both INSPIRE
and EXTEND-IA were comparable in terms of some key baseline
characteristics. However, there were proportionally less patients
with M2 occlusions offered EVT, higher proportion with large
infarct core (thus smaller proportion with target mismatch), and
longer time from stroke onset to hospital arrival in INSPIRE.
Survival Analysis
Based on the published HR of mortality by mRS score for
stroke patients, the Cox regression model showed that INSPIRE
EVT was associated with nominally reduced probability of
death (HR: 0.92, 95% CI: 0.78–1.08, p = 0.287, Figure 1).
Older age, being male, and higher baseline volume of
baseline infarct core contributed to decreased probability of
survival (p < 0.05), whereas baseline NIHSS (p = 0.146)
was not statistically significant for the probability of survival
(Supplementary Table 2). The subgroup analysis including
patients with ICA or M1 occlusions suggested that EVT led
to a reduced probability of mortality (HR: 0.82, 95% CI: 0.71–
0.96, p = 0.012) with older age, male gender, and higher
baseline NIHSS accounting for lowered probability of survival
(Supplementary Figure 3).
The long-term estimation based on the EXTEND-IA data
reported that EVT was associated with a better probability of
survival with a HR of 0.42 (95% CI: 0.22–0.82, p = 0.01) than
corresponding controls with no EVT (8).
DALYs Lost
EVT in INSPIRE LVO patients was associated with fewer DALYs
lost (11.04, 95% CI: 10.45–11.62) than those not receiving EVT
(12.13, 95% CI: 11.75–12.51) or a difference in reduction of
1.09 DALYs (95% CI: −1.76 to −0.43, p = 0.002). Similar
results were also observed for YLL and YLD, with corresponding
avoided YLL of −0.68 (95% CI: −1.18−0.18, p = 0.009) and
YLD of −0.47 (95% CI: −0.98 to 0.03, p = 0.074). The
raw distribution of DALYs by treatment groups is presented
in Supplementary Figure 4. In the scenario where the age
weighting and discounting were applied, the difference in DALYs
saved was smaller (as future life years were discounted) (Table 2).
The unadjusted difference in EXTEND-IA DALYs was 2.72
TABLE 1 | Baseline characteristics of the LVO study population from INSPIRE
and EXTEND-IA.
INSPIRE EXTEND-IA RCT
EVT No EVT EVT No EVT
(N = 178) (N = 584) (N = 35) (N = 35)
Age (mean, SD) 69.7 (14.76) 71.9 (13.52) 68.6 (12.3) 70.2 (11.8)
Male gender (N, %) 95 (53.4%) 301 (51.5%) 17 (49%) 17 (49%)
Baseline NIHSS
(median, IQR)








112 (74–151) 83 (49–133) 106 (76–137) 115 (72–158)
Treatment type (N, %)
EVT + tPA 86 (48.3%) 0 35 (100%)* 0
EVT only 92 (51.7%) 0 0 0
tPA only 0 346 (59.3%) 0 35 (100%)
Target mismatch 156 (87.6%) 452 (77.4%) 100% 100%




95 (43–148) 112 (53–171) 78 (54–112) 80 (56–115)
Median time from
onset to tPA
156 (120–187) 171 (127–211) 127 (93–162) 145 (105–180)
Successful
reperfusion (N, %)
90 (74.4%)** 242 (53.7%)** 35 (100%) 13 (37%)
Occlusion site (N, %)
ICA 53 (29.8%) 151 (25.9%) 11 (31%) 11 (31%)
M1 115 (64.6%) 310 (53.1%) 20 (57%) 18 (51%)
M2 10 (5.6%) 123 (21.0%) 4 (11%) 6 (17%)
Three-month mRS
mRS 0 27 (15.2%) 93 (15.9%) 9 (26%) 6 (17%)
mRS 1 39 (21.9%) 96 (16.4%) 9 (26%) 4 (11%)
mRS 2 19 (10.7%) 68 (11.6%) 7 (20%) 4 (11%)
mRS 3 41 (23.0%) 76 (13.0%) 6 (17%) 4 (11%)
mRS 4 15 (8.4%) 85 (14.6%) 1 (3%) 6 (17%)
mRS 5 8 (4.5%) 60 (10.3%) 0 (0%) 4 (11%)
mRS 6 29 (16.3%) 106 (18.2%) 3 (9%) 7 (20%)
Age, gender, baseline NIHSS, volumes of infarct core and perfusion lesion, and occlusion
locations are not significantly different for patients who received EVT between INSPIRE
and EXTEND-IA participants.
*On the basis of intention-to-treat principle; **57 patients in the EVT and 133 patients
in the no EVT group did not have the 24-h TICI outcome. The proportion of successful
reperfusion was significantly different between the EVT and no EVT groups within INSPIRE
(p < 0.0001).
Baseline core volume, perfusion lesion volume, and penumbra volume are expressed
in ml.
EVT, endovascular thrombectomy; IQR, interquartile range; SD, standard deviation; ICA,
internal carotid artery; tPA, tissue plasminogen activator.
(p = 0.02) (8). In summary, the between-group difference in
DALYs reduction due to EVTwas less in the INSPIRE population
(1.09 DALY saved) than that in the EXTEND-IA RCT (2.72
DALY saved).
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FIGURE 1 | Cox proportional hazards regression for the long-term modeled survival.
TABLE 2 | Results of disability-adjusted life years by endovascular thrombectomy status from INSPIRE and EXTEND-IA.
INSPIRE EXTEND-IA RCT
YLL YLD DALY DALY



















































EVT, endovascular thrombectomy; YLL, years of life lost; YLD, years lived with a disability; DALY, disability-adjusted life year; N.A., not available.
*Not statistically significant (p = 0.074).
Sensitivity Analysis
The analysis by age group showed that in the INSPIRE
population, DALYs saved decreased by age due to the lesser
impact on remaining life expectancy (Figure 2). The larger
difference in DALYs saved −1.90 (95% CI: −3.15 to −0.65) was
observed in the youngest age group (<50 years), whereas this
difference reduced to −0.57 (95% CI: −0.95 to −0.20) in the
oldest age category (>80 years) (Table 3).
The bootstrapping revealed results consistent with the base
case results from GLM analysis (Table 4). The differences in
INSPIRE DALYs between the treatment groups were−0.97 (95%
CI: −1.60 to −0.34, p = 0.002) in the unadjusted analysis
and −0.55 (95% CI: −0.88 to −0.23, p = 0.001) in the
adjusted analysis (Figure 3).
DISCUSSION
This study demonstrated that the clinical outcomes of LVO
patients who undergo EVT LVO in Australia (i.e., INSPIRE)
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FIGURE 2 | Difference in disability-adjusted life years by age category.
TABLE 3 | Results of disability-adjusted life years by age category from INSPIRE.
Age EVT_INSPIRE No EVT_INSPIRE Between-group































EVT, endovascular thrombectomy; DALY, disability-adjusted life year.
resulted in less than half of the DALYs saved compared with
those selected for enrollment in EXTEND-IA. However, EVT
still resulted in significantly better DALY outcomes than those
patients treated with/without thrombolysis in the INSPIRE. The
saved INSPIREDALYs from EVTwere greater in the younger age
group due to their longer life expectancy. The sensitivity analysis
using a bootstrapping technique yielded similar results as the base
case analysis with a slightly smaller difference in saved DALYs.
The smaller between-group difference in DALYs saved after
EVT in INSPIRE compared with EXTEND-IA occurred despite
generally comparable baseline characteristics including age,
occlusion site, baseline NIHSS, ischemic core, and perfusion
lesion volume (6). The primary reason for the discrepancy is
that a higher proportion of patients randomized to EVT in the
EXTEND-IA trial achieved much better functional outcomes
proportionally at 3 months than observed from the current
registry data: over 72% of patients achieved a mRS score ≤2,
whereas this proportion was only 48% in the real-world data
(6), probably due to offering EVT to extended time window
patients (i.e., around 17% of patients received EVT beyond 6 h of
the normal time window) or patients without a target mismatch
(i.e., ∼12% of EVT patients did not have a target mismatch, and
6% of patients had a core volume >70ml) in INSPIRE. Indeed,
the outcomes achieved in EXTEND-IA are exceptionally high
by any standard and indicate rigorous adherence to computed
tomography perfusion (CTP) mismatch criteria, as opposed to
MR CLEAN, for example, which did not use CTP selection, and
the corresponding 3-month mRS 0–2 was 32.6% (3). It is worth
noting that the key driver for the post-stroke survival and DALYs
avoided was the HR of mortality according to the 3-month mRS
score (i.e., higher mRS score is associated with higher HR in
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TABLE 4 | Sensitivity analysis from bootstrapping INSPIRE.
Unadjusted Adjusted
INSPIRE between-group p-value INSPIRE between-group p-value
difference difference
YLL −0.63 (95% CI: −1.12, −0.15) 0.011 −0.36 (95% CI: −0.66, −0.06) 0.018
YLD −0.27 (95% CI: −0.56, 0.01) 0.063 −0.16 (95% CI: −0.32, −0.00) 0.046
DALY −0.97 (95% CI: −1.60, −0.34) 0.002 −0.55 (95% CI: −0.88, −0.23) 0.001
YLL, years of life lost; YLD, years lived with a disability; DALY, disability-adjusted life year.
FIGURE 3 | Sensitivity analysis for difference in disability-adjusted life years from bootstrapping.
terms of overall mortality). The substantial difference in the
proportion of patients with favorable mRS score (≤2) between
the RCT and the real-world post-EVT (i.e., patients with severe
disability are more likely to die in the following years than those
with mild disability) resulted in the difference in the YLL and
subsequently led to increased YLD due to the higher disability
weight associated with poorer mRS outcome.
The survival analysis and 3-month outcomes did not show
that INSPIRE EVT was significantly better than the no EVT
treatment group. However, when restricting the analysis to
patients with ICA or M1 occlusion, both analyses suggested that
INSPIRE EVT was associated with better probability of survival
and mRS outcome. One possible explanation for this is that the
non-EVT patients from INSPIRE had the highest proportion
of M2 occlusions (21%), whereas INSPIRE EVT patients had
the lowest proportion of M2 occlusions (5.6%), in comparison
with the proportions from EXTEND-IA (between 11 and 17%).
Patients with M2 occlusion inherently have a better prognosis
than patients with more proximal occlusion (25). The high
proportion of M2 occlusion patients in the no EVT group from
INSPIRE probably contributed to the non-significant difference
in both survival and 3-month mRS outcomes for EVT vs no EVT
in INSPIRE.
This study also showed that younger patients generated
greater DALY savings regardless of the treatment received; this
is echoed by the significant economic burden of stroke due
to young patients primarily due to productivity losses (26–28).
The substantial burden of young stroke warrants national policy
consideration and a targeted campaign to raise awareness of the
disease in this young age group.
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Quantification of DALYs from real-life data bears two policy
implications: (i) the DALY estimation based on tightly controlled
research trial data is not directly generalizable to everyday clinical
practice. In the real-world, the selection of patients who receive
EVT may not be exactly the same as the eligibility criteria for the
trials, which leads to the variation in the functional outcomes. (ii)
Resource allocation, guideline formulation, and priority setting
in stroke treatment and prevention should preferably be based
on real-world data given the potential risk of overestimation
of intervention benefit from the trials. In addition, using the
incremental cost due to EVT from EXTEND-IA and the DALY
reduction between the EVT and no EVT groups from INSPIRE, it
was estimated that the incremental cost effectiveness ratio (ICER)
was A$8,838 (95% CI: $5,454–$22,726). This result suggests that
with the uncertainty considered in the economic analysis, the
EVT procedure may not necessarily be cost-effective in some
developing countries (i.e., the upper bound of the ICER may well
exceed the willingness to pay per DALY threshold).
Our study has several key strengths. Firstly, the analysis
was based on routine clinical practice registry data for stroke
including both EVT and intravenous alteplase treatment over
the past 5 years from most of the states/territories in Australia.
However, there is no doubt that this still represents a minority
of patients treated with EVT in all Australian centers over the
study period. Secondly, INSPIRE participants not only include
those who received EVT meeting CTP mismatch criteria from
trials, such as EXTEND-IA, but also incorporate a minority of
patients outside of these criteria who were treated with EVT
at clinicians’ discretion. Thirdly, individual patient-level data
facilitated the analysis that adjusted for baseline characteristics
(age, gender, baseline NIHSS, baseline penumbra volume, and
time from stroke onset to hospital arrival) to accurately estimate
the difference in DALYs avoided between the two groups. This
study, however, is not without limitations. Any recurrent stroke
and other cardiovascular events beyond 3 months were not
simulated in the long-term when estimating life expectancy.
Given these events would impact on the patients from both
treatment groups (although it could be argued that patients
with better mRS outcome would have lower risk of experiencing
follow-up adverse cardiovascular events), this is considered to
not favor EVT. Second, the differences in patient characteristics
between the INSPIRE and the EXTEND-IA including more
patients with large infarct core, absence of target mismatch, and
longer time from stroke onset to hospital arrival in INSPIRE may
restrict comparability. However, the INSPIRE group represents
the experience of EVT and standard care without EVT in the real-
world where differences in characteristics do exist for patients
from both treatment groups, compared with the two randomized
groups in EXTEND-IA. Lastly, we are not able to comment on
unmeasured patient factors (i.e., premorbid mRS that was not
mandated in the INSPIRE) that may have excluded a patient from
a trial, such as EXTEND-IA, but led to their inclusion in INSPIRE
as part of everyday practice. While this point leads to the strength
of this analysis on the implementation of the evidence, we are
unable to identify the key drivers of these influencing factors.
The recently published DIRECT-MT and SKIP trials assessed
whether EVT alone was inferior to the alteplase prior to EVT,
with the former demonstrating the non-inferiority (mRS shift,
adjusted OR: 1.07, 95% CI: 0.81–1.40, p= 0.04) (29–31). It would
be of research interest to compare the long-term health gains
from bridging alteplase in real-world from INSPIRE vs. DIRECT-
MT/SKIP RCTs. However, we expect the cost implications of such
direct treatment, where there is limited clinical change, to be
minimal since the majority of costs arise from the long-term care
of patients.
CONCLUSIONS
EVT was associated with significant savings in DALYs compared
with usual care/IVT in real-world Australian practice, but
the benefit was smaller than that seen in EXTEND-IA. The
incomplete translation of the EXTEND-IA results into real-
world practice is likely related to multiple factors including
patient selection.
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